Erlotinib API Manufacturers

Looking for Erlotinib 183321-74-6?

Description:

Here you will find a list of producers, manufacturers and traders of Erlotinib. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Erlotinib 

Synonyms:

Erlotinib , OSI-774 , Erlotinib Hydrochloride  

Cas Number:

183321-74-6 

DrugBank number:

DB00530 

Unique Ingredient Identifier:

J4T82NDH7E

Erlotinib is a type of Protein kinase inhibitors

Protein kinase inhibitors are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in targeted cancer therapies. These inhibitors specifically target and block the activity of protein kinases, enzymes that regulate various cellular processes, including cell growth, division, and signal transduction.

Protein kinase inhibitors function by binding to the active site of protein kinases, preventing them from phosphorylating specific proteins and disrupting intracellular signaling pathways. This targeted approach inhibits the uncontrolled growth and proliferation of cancer cells, ultimately leading to their death.

The development of protein kinase inhibitors has revolutionized cancer treatment by providing more effective and less toxic alternatives to traditional chemotherapy. These drugs have demonstrated impressive results in the treatment of various cancers, including lung, breast, and leukemia.

The pharmaceutical industry invests heavily in research and development to discover novel protein kinase inhibitors with improved potency, selectivity, and pharmacokinetic properties. High-throughput screening, computational modeling, and structure-activity relationship studies are employed to identify potential lead compounds.

The success of protein kinase inhibitors in treating cancer has spurred significant interest in this subcategory of APIs. Ongoing research aims to expand their applications to other diseases, such as autoimmune disorders and neurological conditions.

In conclusion, protein kinase inhibitors are a valuable class of pharmaceutical APIs with immense potential for targeted cancer therapies. Continued advancements in this field hold promise for improved treatment outcomes and enhanced patient care.

Erlotinib (Protein kinase inhibitors), classified under Anticancer drugs

Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.

Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.

These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.

Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.

• Shilpa Medicare Ltd from India
• Shandong Loncom Pharmaceutical CO.,Ltd. from China
• SENOVA Technology Co., Ltd. from China
• Gonane Pharma from India
• TIEFENBACHER API + Ingredients from Germany
• Beijing Lunarsun Pharma from China
• Fresenius Kabi Onc. from India
• Laurus Labs from India
• Fabbrica Italiana Sintetici (FIS) from Italy
• Natco Pharma from India
• Shandong Luoxin from China
• Beijing Hope from China
• Fujian South Pharma from China
• Intas Pharma from United Kingdom
• Kolon Life Science from South Korea
• Asymchem from China
• Adley Formulations from India
• Teva API from Israel
• Qilu Antibiotics from China
• Reliance Life Sciences from India
• Mac Chem Products from India
• Hetero Labs from India
• Shaoxing Hantai Pharma from China
• Sun Pharma from India
• Mylan from India
• Cipla from India
• MSN Labs. from India
• Alembic Pharma from India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.